Hi,   I recently joined PharmeMed and I’m a 3rd year Pharmacy student in the U.K. looking for potential placement, internship,part time job opportunities in my field. I am also available to network as well. In my spare time, you can catch me reading novels by African authors and honestly, just scrolling on Tiktok. Feel free to message me. ????????‍♀️

https://www.pharmatimes.com/news/sanofis_btk_inhibitor_tolebrutinib_gains_promising_long-term_ms_data_1380733

Hello everyone,
I’m looking for some help please. My free online learning with LinkedIn has now come to an end. Does anyone know of any free online courses I could do to do with the pharmaceutical industry please?
Any help or advice would be much appreciated please.

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, sat down with me to discuss her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing the full potential of cell & gene therapy, and much more.

The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan) Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
The FDA granted BTD based on data from the DESTINY-Breast03 phase 3 trial presented during the European Society for Medical Oncology (ESMO) Congress 2021. The results of the phase 3 trial showed that Enhertu reduced the risk of disease progression or death by 72% vs trastuzumab emtansine (T-DM1). Nearly all patients treated with Enhertu were alive at one year (94.1%) compared to 85.9% of patients treated with T-DM1.
Enhertu is a HER2-directed antibody drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo that has now been granted four Breakthrough Therapy Designations, including two in breast cancer
A breakthrough therapy designation is given to accelerate the development and regulatory review of potential new medicines for serious condition that address a significant unmet medical need.
Breast cancer remains the most common cancer worldwide, with more than two million cases diagnosed in 2020, resulting in nearly 685,000 deaths globally. Approximately one in five cases of breast cancer are considered HER2-positive.
Read more: http://www.pmlive.com/pharma_news/fda_grants_enhertu_breakthrough_therapy_designation_in_breast_cancer_1379785

US biotech company Mirati Therapeutics announced positive Phase II results for its investigational treatment adagrasib as a treatment for KRAS-mutated lung cancer.
The Phase II KRYSTAL-1 study is evaluating adagrasib in patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, prior to systemic therapy.
Adagrasib is an investigational oral small-molecule inhibitor of KRAS G12C that is optimised to sustain target inhibition.
The analysis, which was completed in the intent-to-treat population, showed adagrasib demonstrated an objective response rate (ORR) of 43% and a disease control rate of of 80%.
"The KRAS mutation has historically been challenging to target, leaving patients with limited treatment options," said Charles Baum, president and chief executive officer, Mirati Therapeutics.
"These positive topline data further strengthen our belief in adagrasib as a potentially differentiated therapy for patients with non-small cell lung cancer harbouring the KRASG12C mutation. We look forward to submitting our New Drug Application to the US Food and Drug Administration in the fourth quarter of 2021 and advancing our expanding adagrasib development program, which includes numerous monotherapy and combination studies in KRASG12C-mutated solid tumours,” he added.
Read more: https://www.pharmatimes.com/news/miratis_adagrasib_scores_encouraging_results_in_kras-mutated_lung_cancer_1378148

Michael Wilson and Craig Knox, co-founders of DrugBank, discuss how their comprehensive drug database can be used together with AI and machine learning for drug discovery and repurposing, clinical research, uncovering of patient insights, precision medicine, and much more.

Natalie Yeadon, CEO & Co-Founder at Impetus Digital, provides insight into how COVID has changed clinical trials.

As a Pharma leader, you are in a great position to raise awareness around the climate crisis and its impact on human health. Learn how you can start this conversation with your team by reading our latest Top-10 article: https://www.impetusdigital.com/2021/07/15/top-10-ways-that-pharma-teams-can-fight-the-climate-crisis/

Novavax has launched a Phase I/II study evaluating a combination vaccine for the prevention of both COVID-19 and seasonal influenza, the US biotech company announced today.
The study will evaluate the safety and immunogenicity of a combination vaccine, using Novavax’s flu and COVID-19 vaccines.
The trial combines the company’s recombinant protein-based COVID-19 jab NVX-CoV2372 and NanoFlu vaccine candidates with Novavax’s Matrix-M adjuvant into a single formulation.
The trial will aim to enrol 640 healthy adults, aged 50- to 70-years-old, who will have been either previously infected with the SARS-CoV-2 virus or vaccinated with an authorised vaccine at least eight weeks prior to enrolment.
"This study is the first-of-its-kind to evaluate the vaccine's potential to induce a robust immune response, augmented by our Matrix-M adjuvant, against two life-threatening diseases simultaneously," said Gregory M. Glenn, president of research and development, Novavax.
Read more: https://www.pharmatimes.com/news/novavax_begins_covid-19,_flu_combination_vaccine_trial_1376450

Hi everyone.  I am helping Microbion Corporation fill an important role of Director of Pharmacology and Toxicology.  You can read more about it and apply here: https://www.microbioncorp.com/about/careers

2021 may go down in history as the year when everything changed in Alzheimer’s disease.
Following the approval of Biogen’s Aduhelm (aducanumab) in June, Eli Lilly has created a new business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration.
This includes the company’s potential drug for Alzheimer’s disease, donanemab, which received breakthrough therapy designation in June based on its phase 2 data.
Bio-Medicines will actually split in two: Lilly Neuroscience will be overseen by Anne White, who has guided Lilly Oncology for several years, and Lilly Immunology will be led by current Lilly Bio-Medicines head, Patrik Jonsson.
Jacob (Jake) Van Naarden, currently chief executive officer of Loxo Oncology, will bring together and lead Loxo and Lilly Oncology, and join Lilly's executive committee.
Although Alzheimer’s disease is the sixth leading cause of death in the US, until now there were no therapies that treated the course of the disease. Biogen’s Aduhelm and Lilly’s donanemab are the first new drugs for more than two decades in the therapy area, but they are not without controversy.
Read more: http://www.pmlive.com/pharma_news/lilly_restructures_in_preparation_for_alzheimers_drug_launch_1375423

Notice me

Notice me

My name is Erianna Bass, a recent Masters of Science in Biomedical Sciences graduate from Campbell University. My goal is to obtain a clinical research management position that utilizes skills in biomedical sciences and public health experiences to improve the health and well-being of others.